We use cookies to customize content for your viewing and for analytics. If you continue to browse this website, we will assume that you are happy to receive all our cookies. For further information please read our cookie policy.
Stryker (NYSE:SYK) announced today the acquisition of privately-held HyperBranch Medical Technology, Inc. for a total equity value of approximately $220 million in an all cash transaction. HyperBranch is dedicated to developing medical devices based on its proprietary polymers and cross-linked hydrogels. Its Adherus AutoSpray Dural Sealant product is one of only two FDA-approved dural sealants on the market.
See the full release here.